Last reviewed · How we verify
Tafasitamab plus lenalidomide — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Tafasitamab plus lenalidomide (Tafasitamab plus lenalidomide) — MorphoSys AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tafasitamab plus lenalidomide TARGET | Tafasitamab plus lenalidomide | MorphoSys AG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tafasitamab plus lenalidomide CI watch — RSS
- Tafasitamab plus lenalidomide CI watch — Atom
- Tafasitamab plus lenalidomide CI watch — JSON
- Tafasitamab plus lenalidomide alone — RSS
Cite this brief
Drug Landscape (2026). Tafasitamab plus lenalidomide — Competitive Intelligence Brief. https://druglandscape.com/ci/tafasitamab-plus-lenalidomide. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab